Actavis acquired Allergan for approximately $70.5 billion in a cash-and-stock transaction, combining Actavis's generics scale with Allergan's branded specialty portfolio anchored by Botox. The combined company adopted the Allergan name post-close.
Did it work? Outcome assessment
Value created via Teva divestiture and Botox growth but entity sold to AbbVie for $63B
Strategic verdict
Partially Achieved
Assessment window: 5yr post-close.
Key facts
AnnouncedNov 17, 2014
ClosedMar 17, 2015
Deal value$70.5B
Deal typeAcquisition/Merger
Therapeutic areaGastroenterology, Neurology, Oncology, Ophthalmology, Women's Health